Attributes | Values |
---|
rdf:type
| |
Description
| - alpha-Tocopheryl succinate (TOS) exerts selective toxicity to the cancer cells and anticancer activity in vivo. Yet, no suitable formulation of TOS for medical application has been reported. We developed and characterised a stable lyophilised liposome-based TOS formulation. TOS (15 mol%) was incorporated into large oligolamellar vesicles composed of soy phosphatidylcholine by the method of lipid film hydration followed by extrusion through polycarbonate filters. Stabilised liposomal formulation was prepared by lyophilisation in the presence of sucrose (molar ratio lipid/sucrose, 1:5). The size distribution of the liposomes (130-140 nm, polydispersity index 0.14) as well as the stable lipid and TOS contents were preserved during storage in the lyophilised form for at least 6 months. The data indicate good physical and chemical stability of the lyophilised preparation of TOS liposomes that can be used in clinical medicine.
- alpha-Tocopheryl succinate (TOS) exerts selective toxicity to the cancer cells and anticancer activity in vivo. Yet, no suitable formulation of TOS for medical application has been reported. We developed and characterised a stable lyophilised liposome-based TOS formulation. TOS (15 mol%) was incorporated into large oligolamellar vesicles composed of soy phosphatidylcholine by the method of lipid film hydration followed by extrusion through polycarbonate filters. Stabilised liposomal formulation was prepared by lyophilisation in the presence of sucrose (molar ratio lipid/sucrose, 1:5). The size distribution of the liposomes (130-140 nm, polydispersity index 0.14) as well as the stable lipid and TOS contents were preserved during storage in the lyophilised form for at least 6 months. The data indicate good physical and chemical stability of the lyophilised preparation of TOS liposomes that can be used in clinical medicine. (en)
|
Title
| - Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation
- Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation (en)
|
skos:prefLabel
| - Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation
- Lyophilised liposome-based formulations of alpha-tocopheryl succinate: preparation and physico-chemical characterisation (en)
|
skos:notation
| - RIV/00027162:_____/10:#0000617!RIV11-AV0-00027162
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(KAN200520703), Z(AV0Z50520701), Z(MZE0002716202)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00027162:_____/10:#0000617
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - alpha-tocopheryl succinate; apoptosis; cancer; extrusion; liposome; lyophilisation; nanotechnology; particle size; stability; vitamin E analogues (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Journal of Pharmaceutical Sciences
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Koudelka, Štěpán
- Mašek, Josef
- Turánek, Jaroslav
- Neužil, J.
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |